Add BrightSurf on Google Email

Family history, gene variants put black men at risk for early prostate cancer

A recent study by Duke University researchers has identified key risk factors for Black men diagnosed with early-onset prostate cancer. Genetic variants and a family history of cancer are associated with an increased risk of developing the disease. The study's findings could help reduce racial disparities in prostate cancer outcomes.

SourceDuke University Medical Center·JournalJCO Precision Oncology·DateNov 29, 2022

Ethnic diversity and disparities in access to genetic testing impact prostate cancer development and treatment, research shows

Research emphasizes the importance of ethnically diverse prostate cancer genomics data and accessible genetic testing. Variations in genomic landscape of prostate cancer were observed in Chinese men compared to Western cohorts, with lower mutation rates in driver genes such as TP53 and PTEN.

SourceEuropean Society for Medical Oncology·JournalAnnals of Oncology·DateNov 28, 2022

Drug triggers immune cells to attack prostate cancer

A single drug compound attacks prostate cancer on several fronts by triggering immune cells to attack, helping them penetrate the tumor, and cutting off its ability to use testosterone as fuel. The study found that the drug activates anti-cancer T cells in a novel way and increases their ability to penetrate tumors.

SourceWashU Medicine·JournalNature Communications·DateNov 22, 2022

Anti-cancer drugs, olaparib and adavosertib, work best when given sequentially in patients with advanced tumours driven by DNA damage response mutations: results from Phase Ib STAR clinical trial

A Phase Ib clinical trial found that sequential administration of PARP inhibitor olaparib and WEE1 inhibitor adavosertib is safe and well-tolerated, with promising signs of anti-tumor activity in patients with advanced cancers driven by DNA damage response mutations. The combination showed durable responses in patients with resistant c...

SourceEuropean Organisation for Research and Treatment of Cancer·TypeRandomized controlled/clinical trial·DateOct 27, 2022

Metastasis-directed radiation therapy plus hormone therapy improves progression-free survival for men with advanced prostate cancer

The EXTEND trial found that combining metastasis-directed radiation therapy with intermittent hormone therapy improved progression-free survival in men with oligometastatic prostate cancer. The treatment also prolonged the time men could safely maintain normal testosterone levels, preserving their quality of life.

Lower prostate cancer screening rates associated with subsequent increase in advanced cancers

A large-scale analysis of VA medical centers found that facilities with lower yearly PSA screening rates had higher rates of metastatic prostate cancer in subsequent years. The study supports the benefits of prostate cancer screening in reducing metastatic prostate cancer risk, particularly for high-risk groups like Black patients.

SourceAmerican Society for Radiation Oncology·JournalJAMA Oncology·DateOct 24, 2022

New analysis led by UCLA Jonsson Comprehensive Cancer Center finds timing androgen-deprivation therapy with radiation therapy improves outcomes in localized prostate cancer

A new analysis by UCLA Jonsson Comprehensive Cancer Center found that men with prostate cancer benefit from adding androgen deprivation therapy to radiation treatment. The study showed improved metastasis-free survival for patients receiving short-term ADT before or after radiation, especially in those receiving prostate-only RT.

SourceUniversity of California - Los Angeles Health Sciences·JournalJournal of Clinical Oncology·TypeMeta-analysis·DateOct 21, 2022

Alliance Foundation trials study finds combination hormonal therapy delivered in finite period improves PSA levels in patients with prostate cancer

A randomized phase III trial found that combination hormonal therapy, delivered for a finite treatment interval of 12 months, more durably suppresses PSA levels compared to hormone injections alone. The treatment approach improved disease progression in patients with high-risk biochemically relapsed prostate cancer.

High-volume surgeons no better at reducing postoperative incontinence

A study from the University of Gothenburg found that the number of surgeries performed by a urology surgeon has no effect on men's risk of developing postoperative urinary incontinence after prostate cancer surgery. The researchers analyzed data from over 4,600 men who underwent robot-assisted radical prostatectomy between 2017 and 2019.

SourceUniversity of Gothenburg·JournalScandinavian Journal of Urology·TypeSurvey·DateSep 8, 2022

New research shows PSMA PET/CT imaging changes management for close to 50 percent of prostate cancer patients

A new study shows that PSMA PET/CT imaging can change treatment plans for nearly 50% of patients with prostate cancer recurrence after radical prostatectomy. The imaging technique detected disease in 46.9% of patients, leading to major changes in treatment plans, including recommendations for additional treatments.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateSep 7, 2022

Early detection by Tango

The Tango assay combines accumulation and a logical AND gate operation to identify prostate cancer biomarkers in blood samples. It achieves 91% accuracy in detecting prostate cancer in just 15 minutes, offering a non-invasive alternative to biopsies.

SourceWiley·JournalAngewandte Chemie International Edition·TypeExperimental study·DateJul 20, 2022

PSA-based endpoints should not be used as surrogate endpoints for overall survival in men with recurrent prostate cancer at this time

A study published in the Journal of Clinical Oncology found that biochemical failure is not a reliable surrogate endpoint for overall survival in patients with recurrent prostate cancer. The researchers recommend considering metastasis-free survival (MFS) as the best surrogate endpoint for overall survival in this population.

SourceNRG Oncology·JournalJournal of Clinical Oncology·DateJun 29, 2022

Moffitt study shows adaptive therapy improves outcomes, reduces care costs for prostate cancer patients

A Moffitt study shows that adaptive therapy using abiraterone improves patient outcomes and reduces care costs. The approach delays treatment withdrawal to prevent resistant cells from proliferating, leading to longer median time to progression and overall survival.

SourceH. Lee Moffitt Cancer Center & Research Institute·JournaleLife·TypeRandomized controlled/clinical trial·DateJun 29, 2022

Moffitt researchers contribute to discovery of mechanism leading to drug resistance in prostate cancer

A new study published in Science Translational Medicine reveals that consecutive molecular modifications of the androgen receptor can contribute to drug resistance in prostate cancer. Researchers identified a potential treatment approach using an ACK1 inhibitor to block this resistance.

SourceH. Lee Moffitt Cancer Center & Research Institute·JournalScience Translational Medicine·TypeExperimental study·DateJun 15, 2022

New LLU study associates intake of dairy milk with greater risk of prostate cancer

A new Loma Linda University study associates high dairy milk intake with a significantly increased risk of prostate cancer. Researchers found no association between non-dairy calcium and prostate cancer risk, suggesting substances other than calcium contribute to the increased risk.

SourceLoma Linda University Adventist Health Sciences Center·JournalAmerican Journal of Clinical Nutrition·TypeObservational study·DateJun 8, 2022

New cancer subtype may illuminate treatment strategy

Researchers have identified a previously unrecognized form of hormone therapy-resistant prostate cancer and found promising drug targets to treat it. The discovery opens the door to developing therapies that specifically target this disease, which accounts for approximately a quarter of castration-resistant prostate cancers.

SourceWeill Cornell Medicine·JournalScience·DateMay 27, 2022

Common prostate cancer medications may be less safe than previously thought

Research found that men taking abiraterone or enzalutamide plus hormone therapy had a higher risk of metabolic and cardiovascular issues than those undergoing hormone therapy alone. This increased risk was observed in patients with Medicare health insurance, who were significantly older than those in clinical trials.

SourceMichigan Medicine - University of Michigan·JournalJNCI Journal of the National Cancer Institute·DateMay 25, 2022

Men with prostate cancer have higher risk of serious blood clots

A large-scale study has found that men with prostate cancer have a 50% higher risk of developing serious and potentially fatal blood clots during the five years after their diagnosis. This increased risk is significant because venous thromboembolism (VTE) is a leading cause of death among people with cancer.

SourceBMJ Group·JournalBMJ Open·TypeObservational study·DateMay 23, 2022

Reliable diagnostics at the tip of your finger

Researchers developed a biosensor using nanostructured and nanoporous surfaces to detect biomarkers in clinical samples, overcoming technical challenges of small sample amounts. The new technology can provide quick and accurate diagnoses for diseases like prostate cancer without needing dilution or preprocessing steps.

SourceInstitute for Basic Science·JournalAdvanced Materials·TypeExperimental study·DateMay 17, 2022

Benefits of PSA prostate cancer screening found to be more favorable than previous estimates, especially for blacks

New research suggests that PSA screening has remarkably favorable tradeoffs, particularly for Black men, who disproportionately bear the burden of prostate cancer mortality and morbidity. The study's findings support the use of PSA screening for high-risk groups, including Black men, and highlight the need to revise clinical guidelines...

SourceWeill Cornell Medicine·JournalNEJM Evidence·DateMay 15, 2022

Researchers find favorable tradeoffs of PSA screening for prostate cancer

Research suggests that PSA screening can prevent a significant number of prostate cancer deaths, with lower numbers than previously estimated. The study's findings support the benefits of PSA screening, especially for young healthy men and Black men, who have historically been underrepresented in clinical trials.

SourceUniversity Hospitals Cleveland Medical Center·JournalNEJM Evidence·TypeData/statistical analysis·DateMay 15, 2022